Tygacil Drug Use Investigation (Tigecycline Evaluation Study For Safety And Effectiveness In Patient Infected With Multi-drug Resistance.)
To retrospectively collect the effectiveness and safety information of tigecycline related to their appropriate use in daily practice.
Observational Model: Case-Only Time Perspective: Retrospective
Target Follow-Up Duration
The patients whom an investigator involving B1811187 prescribes the tigecycline (Tygacil).
Skin Disease, Infectious
Drug: Tigecycline (Tygacil)
Tigecycline 50 mg intravenously. Therapy conducted according to Japanese LPD of Tygacil. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
Other Name: Tygacil, Tigecycline
Subjects who are treated with tigecycline
Intervention: Drug: Tigecycline (Tygacil)
* Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
June 16, 2017
Primary Completion Date
June 16, 2017 (Final data collection date for primary outcome measure)
All patients who are prescribed tigecycline (Tygacil).
Subject who have been prescribed tigecycline (Tygacil).
Sexes Eligible for Study:
Child, Adult, Senior
Accepts Healthy Volunteers
Contact information is only displayed when the study is recruiting subjects
Listed Location Countries
Removed Location Countries
Other Study ID Numbers
Has Data Monitoring Committee
U.S. FDA-regulated Product
IPD Sharing Statement
Pfizer CT.gov Call Center
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below: